通化东宝：对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金_老虎社区_美港股上老虎

通化东宝：对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金

互动易2025-02-21

有投资者向通化东宝提问，请问公司THDBH120未来上市后，药明公司要从该药的销售额中分的多大的提成比例？公司回答表示，感谢您对公司的关注。根据公司2021年3月所披露的合作公告，对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2513254177?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-21 16:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2513254177","market":"sh","top_or_hot":-1,"title":"通化东宝：对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金","media":"互动易","content":"<div>\n<p>有投资者向通化东宝提问， 请问公司THDBH120未来上市后，药明公司要从该药的销售额中分的多大的提成比例？公司回答表示，感谢您对公司的关注。根据公司2021年3月所披露的合作公告，对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金。</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221170807abd755ca&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>通化东宝：对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n通化东宝：对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-21 16:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221170807abd755ca&s=b><strong>互动易</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>有投资者向通化东宝提问， 请问公司THDBH120未来上市后，药明公司要从该药的销售额中分的多大的提成比例？公司回答表示，感谢您对公司的关注。根据公司2021年3月所披露的合作公告，对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金。</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221170807abd755ca&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1997245094.SGD","symbol_name":"安联神州A股基金AT Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221170807abd755ca&s=b","article_id":"2513254177","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221170807abd755ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2513254177","pubTimestamp":1740127914,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"有投资者向通化东宝提问， 请问公司THDBH120未来上市后，药明公司要从该药的销售额中分的多大的提成比例？公司回答表示，感谢您对公司的关注。根据公司2021年3月所披露的合作公告，对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600867":"通化东宝","603259":"药明康德","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK0188":"融资融券","BK0196":"行业龙头","BK0239":"医药制造","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0216":"研究试验","LU1997245177.USD":"安联神洲A股基金"},"translate_title":"Tonghua Dongbao: Regarding the net sales revenue of the company's THDBH120 for injection after its future listing, Shanghai WuXi AppTec will obtain corresponding sales commission and sales milestone fee according to the progressive method and proportion (no higher than 5.5%) and amount agreed in the technology transfer contract and cooperative development contract","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600867":1,"603259":1},"content_text":"有投资者向通化东宝提问， 请问公司THDBH120未来上市后，药明公司要从该药的销售额中分的多大的提成比例？公司回答表示，感谢您对公司的关注。根据公司2021年3月所披露的合作公告，对于公司注射用THDBH120未来上市后取得的净销售收入，上海药明康德按照技术转让合同和合作开发合同约定的分段累进方式和比例（不高于5.5%）及数额获得相应的销售提成及销售里程碑金。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}